Regulation of HMG CoA reductase activity is the primary approach for controlling de novo cholesterol synthesis, while abnormal activation can lead to hepatic cholesterol accumulation and hypercholesterolemia. The gene discussed is HMGCR; the disease is Hypercholesterolemia.